Given that TRAF3 silencing in GBM is largely driven by promoter hypermethylation, a viable therapeutic strategy may involve using demethylating agents, such as DNA methyltransferase inhibitors (DNMTis), to restore TRAF3 expression. Here, TRAF3 is linked to glioblastoma.